Engflag

Setizin -CP

Quick links to important sections

Setizin -CP

Setizin -CP_EN

Method of action: Antitussive, Nasal Preparations

Treatment option: Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Setizin -CP

Quick Facts

Property Description
Active Ingredients Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride
Form Tablet (Oral)
Pharmacological Class Upper Respiratory Combination (Antihistamine + Decongestant)
General Purpose Relief from Allergic Rhinitis and Nasal Congestion
Origin Synthetic

Setizin-CP is a synthetic, fixed-dose combination medication taken via the oral route, classified as an Upper Respiratory Combination drug. Its primary function is to relieve symptoms of allergic rhinitis and hay fever by simultaneously addressing both the allergic reaction and the associated nasal congestion.

What is Setizin-CP and What Type of Drug is it?

Setizin-CP is a combination medicine that includes two distinct active compounds, allowing it to address compound symptoms with a single dose. The product is typically supplied as a solid oral tablet, a format that is clinically recognized for convenient administration. The combination's efficacy in managing both allergy and congestion is well-established in clinical practice, confirming its utility for combined symptoms. This combination provides effective relief by mitigating both the allergic response and the physical obstruction. The drug is categorized by its dual action, combining an antihistamine and a decongestant to provide more comprehensive relief than either ingredient could offer alone. Similar fixed-dose formulations often appear under different trade names, confirming the pharmacological relevance of this dual-compound approach.

What is Setizin-CP Composed Of?

Setizin-CP is composed of two active ingredients: Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride. Cetirizine Hydrochloride functions as the Second-generation H₁ Antihistamine component, blocking the effects of histamine. Pseudoephedrine Hydrochloride acts as the Sympathomimetic Decongestant component, causing a vasoconstriction effect to reduce swelling in the nasal passages. This pairing ensures that the allergic trigger and the resulting physical obstruction are targeted simultaneously by the synthetic formulation. The dual nature of this product confirms its classification as a specialized treatment for symptoms that include significant nasal congestion. The components work together to manage the two major aspects of upper respiratory allergy symptoms.

What is the General Purpose of Setizin-CP?

The general purpose of Setizin-CP is to provide effective relief for the multiple manifestations of seasonal or perennial allergic rhinitis. By combining an antihistamine and a decongestant, the medicine reduces sneezing, watery eyes, and itching while also clearing the feeling of blockage caused by sinus pressure and swollen nasal tissues. A typical neutral use scenario for Setizin-CP is managing the discomfort during peak allergy seasons when congestion significantly impedes normal breathing. The core function of the combined medicine is to manage the two distinct elements of allergy symptoms, thereby providing comprehensive relief from discomfort associated with upper respiratory allergies.

What side effects are possible with Setizin -CP?

Possible side effects and safety information

The official safety profile for Setizin-CP, a fixed-dose combination of an antihistamine (Cetirizine) and a decongestant (Pseudoephedrine), is defined by regulatory agencies based on frequency and affected body system.

Adverse Reactions by Frequency and System

Adverse reactions are classified into frequency categories as documented in official labeling:

  • Common Reactions (ge 1/100 to <1/10): Include effects on the Nervous System such as somnolence (drowsiness), fatigue, headache, and dizziness. Effects on Psychiatric Disorders include insomnia and nervousness. Gastro-intestinal Disorders commonly include dry mouth.
  • Rare Reactions (ge 1/10,000 to <1/1,000): Include hypersensitivity reactions, convulsions, and effects on Cardiac Disorders such as tachycardia (rapid heart rate) and arrhythmia.
  • Frequency Not Known: Includes post-marketing reports of rare, serious events such as Ischaemic Colitis, and specific cerebrovascular events like Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS), which are linked to the decongestant component.

Safety Considerations

The regulatory profile documents specific safety limitations for certain populations:

  • Impaired Function: Caution is advised, and dose adjustment or avoidance is required in patients with severe renal or hepatic impairment, due to potential accumulation of the active ingredients.
  • Age Restriction: The combination product is not recommended for use in children under 12 years of age.
  • General Cautions: The medicine may impair the ability to perform tasks requiring full mental alertness, such as driving or operating machinery, due to the potential for sedation. Caution is also noted for individuals with predisposing factors for urinary retention or pre-existing cardiovascular disease.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents emphasize that in the event of a suspected overdose of Setizin-CP, immediate medical attention is required. The guidance specifically mandates that an individual should get medical help or contact a Poison Control Center right away.

Overdose manifestations, as documented in regulatory labeling, primarily affect the Central Nervous System (CNS) and the Cardiovascular System. Documented CNS signs may include a spectrum of effects, such as somnolence (drowsiness), fatigue, headache, tremor, diarrhoea, and mydriasis (dilated pupils). Pediatric patients may exhibit a specific biphasic presentation, initially showing restlessness or excitement before the onset of drowsiness.

Overdose has the potential to lead to serious or life-threatening outcomes, including seizures and severe tachycardia or cardiac arrhythmias. Due to these possible severe effects, continuous hospital monitoring and observation may be required.

Management of the overdose is officially cited as symptomatic and supportive. Regulatory statements confirm that no specific antidote is known for the cetirizine component, and supportive procedures such as gastric lavage or activated charcoal may be considered, particularly soon after exposure. The severity of overdose is also noted to be potentially greater in both children and older adults.

Therapeutic Uses of Setizin -CP

Understanding Setizin -CP: Main Uses and Benefits

Setizin -CP is a combination medication formulated to address symptoms associated with upper respiratory conditions. It is primarily utilized to provide relief from the discomfort caused by the common cold, hay fever, and various allergies.

Primary Indications

The medication is designed to target several specific symptoms simultaneously:

  • Allergic Rhinitis: It helps manage symptoms such as sneezing, itching, and a runny or blocked nose caused by seasonal allergies (hay fever) or perennial allergies (such as dust or pet dander).
  • Nasopharyngeal Congestion: The formulation works to reduce swelling in the nasal passages, making it easier to breathe through the nose.
  • Ocular Symptoms: It assists in relieving itchy, watery, or red eyes often associated with allergic reactions.
  • Common Cold Symptoms: It is used to alleviate the general malaise, nasal drip, and congestion accompanying viral upper respiratory infections.

Therapeutic Benefits

By combining multiple active agents, Setizin -CP offers several therapeutic advantages for symptom management:

  • Comprehensive Symptom Control: Because it contains both an antihistamine and a decongestant, it addresses the histamine response as well as the physical blockage of nasal airways.
  • Improved Respiratory Comfort: The reduction in mucosal swelling helps clear the sinuses and nasal passages, which can reduce pressure and discomfort.
  • Interruption of the Allergic Cascade: The antihistamine component works to block the effects of histamine, the natural substance in the body that triggers allergic inflammation and secretions.
  • Enhanced Daily Functioning: By mitigating persistent symptoms like sneezing and congestion, the medication helps individuals maintain their regular daily activities with less distraction from physical discomfort.

Regulatory References

  1. NIH MedlinePlus guidance on Cetirizine

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Eligibility for Setizin-CP is defined by official regulatory labeling, primarily due to the decongestant component, Pseudoephedrine. This medicine is absolutely contraindicated (prohibited) in several population groups.

Contraindications

Use is forbidden for individuals with severe uncontrolled hypertension, severe coronary artery disease, or ischaemic heart disease. It is also contraindicated in patients with severe kidney disease (end-stage renal disease) and those with known allergy (hypersensitivity) to the active ingredients or related derivatives. Setizin-CP must not be used by any patient who has taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Age and Restricted Use

The medicine is contraindicated in children under 12 years of age. Use is permitted for adolescents 12 years and older, and adults. Older adults (65 years and older) should use with caution and may require medical guidance. Individuals with moderate liver or kidney impairment require caution, as regulatory documents indicate a dose reduction may be necessary.

Comorbidities and States

Caution is required for patients with diabetes mellitus, hyperthyroidism, glaucoma, or predisposing factors for urinary retention. For pregnancy, professional consultation is mandatory. The medicine is generally not recommended while breastfeeding due to the transfer of active ingredients to the infant and the potential effect on milk supply.

What should I know about interactions with other medicines?

The official regulatory profile for Setizin-CP, a combination of Cetirizine and Pseudoephedrine, is defined by strict prohibitions and documented exposure changes. Co-administration is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to the risk of severe hypertensive crisis. Use with other sympathomimetic agents is also restricted because of the potential for additive vasoconstrictor effects.

Pharmacodynamic and Exposure Interactions

Interaction Type Interacting Agent(s) Official Outcome
Pharmacodynamic Alcohol or CNS Depressants Additive central nervous system (CNS) effects.
Pharmacokinetic Ritonavir Increased plasma concentrations of Cetirizine.
Pharmacokinetic Theophylline (400 mg once daily) Decreased clearance of Cetirizine, increasing its exposure.

Co-administration with Beta-blockers and Cardiac Glycosides (e.g., Digoxin) requires caution due to cardiovascular risk. Population-specific interaction constraints exist, as the product is formally restricted in patients with severe hypertension or coronary artery disease, and those with impaired renal function exhibit reduced Cetirizine clearance, which prolongs its systemic exposure.

Mechanism of Action

The medication acts through two separate mechanistic domains to modulate physiological signaling, leveraging the distinct actions of its two components.

Selective H1 Receptor Blockade: Modulating Inflammatory Signaling

The antihistamine component (Cetirizine) acts as a selective peripheral histamine-1 ( H1) receptor antagonist. This mechanism blocks the activation of these receptors by the mediator histamine, a key component in inflammatory signaling cascades. By engaging this early molecular step, the drug limits the impact of excessive mediator activity and modifies the signaling sequence that affects downstream outcomes such as microvascular permeability and sensory nerve stimulation.

Direct Alpha-Adrenergic Agonism: Dampening Vascular Engorgement

The decongestant component (Pseudoephedrine) targets a separate pathway by acting as a direct alpha-adrenergic receptor agonist. This engages mechanisms that are relevant in the autonomic neural pathways controlling local blood vessel activity. By stimulating alpha-receptors on vascular smooth muscle, the drug initiates a signaling cascade that leads to vasoconstriction (narrowing of the vessels) in the nasal lining. This mechanism results in a regulated state within targeted nasal pathways, contributing to the predictable physiological adjustment of reducing blood flow and limiting tissue engorgement and fluid accumulation.

Dosage and Administration Information

How to Use Setizin-CP

Setizin-CP, a fixed-dose combination containing 5 mg of Cetirizine Hydrochloride and 120 mg of Pseudoephedrine Hydrochloride, is formulated as an Extended-Release (ER) tablet for oral administration. Administration focuses on a precise frequency and specific conditions.

Official Dosing and Frequency

Feature Guideline
Standard Dosing One (1) ER tablet
Frequency Every 12 hours (Twice daily)
Maximum Dose Do not take more than two (2) tablets in 24 hours

Administration Requirements

To ensure the controlled release of the active ingredients, the ER tablet must be swallowed whole with liquid; it must not be broken, chewed, or crushed. The medicine can be taken with or without food. Use is intended for the temporary relief of symptoms; consultation with a healthcare professional is necessary if symptoms persist beyond seven days.

Special Population Rules

While the standard dose is for adults and children 12 years of age and older, specific adjustments may be necessary for some populations. It is indicated that individuals 65 years of age and older or those with known renal (kidney) or hepatic (liver) impairment should consult a healthcare provider. In these cases, a dose reduction, typically to one tablet per day, may be required to align with established medical safety profiles.

Recent Clinical Evidence

Evidence for Symptoms of Allergic Rhinitis (Hay Fever)

Research for this combination medicine relies on randomized controlled trials (RCTs) compared against placebo and single active agents. Studies primarily examined Adults and Adolescents, measuring changes in key allergy symptoms using composite scores, such as the Total Nasal Symptom Score (TNSS), which tracks sneezing, running, and nasal congestion. Short-term trials reported the measurement of changes in these symptom scores. Research provides context on acute symptom patterns but not individual predictions.

Evidence for Chronic Idiopathic Urticaria (Hives)

The evidence base for uncomplicated hives primarily comes from studies focused on the single antihistamine component (Cetirizine) alone. Studies monitored episodic changes in the severity of wheals (hives) and pruritus (itching) using tools like Urticaria Activity Scores (UAS). The data for the fixed-dose combination product itself are still emerging, and evidence is limited for this specific use.

Long-Term Research and Follow-up Durations

The majority of definitive efficacy trials were designed with follow-up durations that were limited, typically lasting only two to four weeks. While these studies are relevant for assessing short-term, episodic symptom patterns, long-term effects are not fully established for the continuous, chronic use of the combination, and data for durability of response are still emerging.

Evidence in Specific Patient Populations

Clinical research has primarily concentrated on Adults and Adolescents. Subgroups of patients with stable underlying conditions (such as mild asthma) were included in some trials. However, data for certain groups (e.g., the elderly) remain insufficient, and the results apply only to the populations studied in the key clinical trials.

Areas of Research Uncertainty and Study Limitations

The evidence landscape contains several limitations. The follow-up durations were limited in many pivotal trials, and comparative evidence is lacking against all available alternative combination products. Furthermore, in some systematic reviews, the evidence quality for certain urticaria outcomes is designated as Low.

Key Studies & References

  1. Cetirizine: Uses, Interactions, Mechanism of Action (DrugBank Monograph)

Frequently Asked Questions (FAQ)

Common questions about Setizin -CP (FAQ)

Q: What is the main difference between Setizin-CP and plain Setizin?

Setizin-CP is described in official documents as a fixed-dose combination product, containing both the antihistamine component, Cetirizine, and the decongestant component, Pseudoephedrine. Plain Cetirizine is the single-ingredient medicine that provides only the antihistamine action.

Q: How quickly should I expect Setizin-CP to start working?

Studies examining the medicine have reported the onset of effects to be approximately 30 minutes after administration. The medicine is formulated as an extended-release tablet designed to provide sustained relief.

Q: How long does the effect of Setizin-CP typically last?

The medicine is formulated to provide sustained relief, which is why official labeling recommends a 12-hour dosing interval. This design aims to cover the period between administrations.

Q: Is Setizin-CP the same kind of medicine as other allergy drugs?

Setizin-CP is classified as an Upper Respiratory Combination drug because it combines an antihistamine and a decongestant. This dual action is a key feature that distinguishes it from single-ingredient allergy treatments.

Q: What is the role of Setizin-CP in managing chronic symptoms?

Official research evidence shows that the majority of clinical efficacy trials for the combination product had limited follow-up durations, typically only two to four weeks. Information regarding the safety and duration of response for continuous, long-term use is still emerging.

Q: Is Setizin-CP suitable for long-term use?

The medication is intended for the temporary relief of symptoms. Official guidance states that consultation with a healthcare professional is necessary if symptoms persist beyond seven days.

Q: Can Setizin-CP affect the results of an allergy skin test?

Since Setizin-CP contains an antihistamine component (Cetirizine), it is generally recognized that antihistamines may interfere with diagnostic test results. Official guidance indicates that it may be required to discontinue use for a period of time before an allergy skin test.

Q: What is the typical timeframe for when Setizin-CP's benefits are noticeable?

Studies examining the medicine have reported that the benefits are noticeable starting approximately 30 minutes after administration. The benefits are sustained throughout the 12-hour dosing period due to the extended-release formulation.

Q: Why do some people report feeling nervous or restless after taking it?

Nervousness is listed as a Common Reaction in the official safety profile. The official product information lists nervousness as an expected effect, which is attributed to the decongestant component.

Q: Is it normal to have a slight headache when first starting Setizin-CP?

Headache is listed as a Common Reaction in the official safety profile for the medicine. This frequency places headache among the generally recognized potential side effects.

Q: Does Setizin-CP interact with caffeine intake?

The decongestant component acts as a sympathomimetic agent, which can stimulate the central nervous system. Using this medicine alongside CNS stimulants like caffeine may lead to additive effects on heart rate and blood pressure. Official guidance notes that this may require caution.

Q: Are there documented cases of allergic reactions to Setizin-CP?

Official regulatory safety profiles list hypersensitivity reactions, including swelling of the face, tongue, or throat, as a Rare Reaction (occurring in ge 1/10,000 to <1/1,000 patients).

Q: What happens if I take Setizin-CP on an empty stomach?

According to official administration guidelines, the Extended-Release tablet is approved to be taken with or without food. Taking it with or without a meal is not described as changing the way the medicine is absorbed.

Q: Are there any warnings about sun exposure while using Setizin-CP?

The active antihistamine component, Cetirizine, has been associated with the potential for photosensitivity (increased skin reaction to sunlight) in rare post-marketing reports. This information indicates that general caution may be warranted regarding sun exposure.

Q: What is the shelf life of Setizin-CP?

A specific shelf life (expiration date) for Setizin-CP is established by the manufacturer and approved by regulatory bodies. This date is determined based on stability testing and indicates the period during which the medicine is expected to remain potent.

Q: Is Setizin-CP associated with any long-term mental health effects?

While acute psychiatric effects such as insomnia and nervousness are listed as common, the potential for long-term mental health effects is not established due to limited trial duration in efficacy studies.

How should Setizin -CP be stored and disposed of?

How to Store and Dispose of Setizin-CP

Official regulatory guidelines define strict conditions for storing and disposing of Setizin-CP to ensure product stability and safety.

Storage Requirements

The tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Storage is prohibited in areas with excess heat, moisture, or freezing, and the medicine should not be kept in a bathroom. For child safety, the medication must be stored in its original, tightly closed container and kept out of the sight and reach of children, utilizing a locked safety cap.

Disposal Instructions

Do not flush unused or expired Setizin-CP down the toilet or throw it into the wastewater system. The preferred method for disposal is using an official drug take-back program or DEA-authorized collection site. If a take-back program is unavailable, mix the tablets with an unappealing substance, seal the mixture in a plastic bag, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Setizin -CP found in:

A-Z Index: